Stocksigma LogoStocksigma Logo

Dr. Lal PathLabs Reports Robust Q2 Performance and Declares Interim Dividend

Dr. Lal PathLabs posted consolidated revenue from operations of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn

Dr. Lal PathLabs Reports Robust Q2 Performance and Declares Interim Dividend

Dr. Lal PathLabs Ltd 路 Change in Management 路 04 Nov 2026, 7:18 pm

Dr. Lal PathLabs Reports Robust Q2 Performance and Declares Interim Dividend Dr. Lal PathLabs posted consolidated revenue from operations of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn. Consolidated net profit rose 27.4% YoY to INR 1,939 mn versus INR 1,522 mn in the prior-year period. The board declared a second interim dividend of INR 5 per share (50% on face value of INR 10) with a record date of 11th Nov'26, and approved further investments of up to INR 49.5 crore in wholly owned subsidiary Dr. Lal PathLabs FZCO.

Original exchange filing (PDF)

More announcements from Dr. Lal PathLabs Ltd

  • Attached 路 11 Nov 2026
  • Attached 路 10 Nov 2026
  • Attached 路 05 Nov 2026
  • Attached 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates 路 04 Nov 2026

All Dr. Lal PathLabs Ltd announcements